The New Paradigm of Veterinary Biologics
Pharos Vaccine, a professional company of research and development in biotechnology,
explores the safe and life-friendly veterinary biologics for industrial and companion animals.
Pharos Vaccine has been performing research and development of vaccines, immuno-therapeutics,
and the other bio-medicines to prevent and care veterinary diseases, which affect seriously industry and society, based on bioscience and bioengineering.
Experts, who have 30 years of experience in the biotechnology, are developing new paradigm veterinary medicines to
become a real lighthouse (Pharos) that lights up the right way toward a happy society for animals and humans as well.
New Paradigm of
Veterinary Vaccine
Pharos Vaccine has been developing veterinary recombinant protein vaccines using immunogenicity enhanced chimeric protein developed by the company’s distinguishing platform technology. The most veterinary vaccines use the pathogens, e.g. virus, as immunogen, which leads to decreased efficacy due to mutations and safety issues due to live pathogen. Chimeric recombinant proteins have immunogenicity but no pathogenicity, which makes it safe, and mutations can be rapidly reflected to allow efficient reaction to disease. Pharos Vaccine has developed and obtained approval for a foot-and-mouth disease vaccine using chimeric recombinant proteins and is on the way to commercialization, and various other veterinary vaccines are under research and development with the application of this technology.
New paradigm of
Veterinary
Immuno-Therapy
All animals have an immune system that defends against invading pathogens by producing antibodies and attacking with immune cells. Pharos Vaccine is developing antibody treatments which can give passive immunity to prevent and care diseases that commonly occur in animals but are difficult to be treated with vaccines or general therapeutics. Also, research and development of cell therapies against canine cancer is driven via collaboration with famous domestic veterinary clinics, by outperforming cell therapy technology of Pharos Vaccine.